WMT - Walmart Inc.
| Previous Close | 96.35 |
| Open | 96.32 |
| Bid | 96.470 x 800 |
| Ask | 96.500 x 1000 |
| Day's Range | 96.26 - 97.12 |
| 52 Week Range | 81.78 - 109.98 |
| Volume | 1,093,243 |
| Avg. Volume | 9,182,098 |
| Market Cap | 280.053B |
| Beta (3Y Monthly) | 0.52 |
| PE Ratio (TTM) | 55.05 |
| EPS (TTM) | 1.751 |
| Earnings Date | Feb 19, 2019 |
| Forward Dividend & Yield | 2.08 (2.19%) |
| Ex-Dividend Date | 2018-12-06 |
| 1y Target Est | 106.81 |
- Market Realist•21 minutes ago
Twitter Has Its Sights Set on India
Updates from Twitter: Product Development, Audience, and India(Continued from Prior Part)A booming advertising market Twitter’s (TWTR) primary business is advertising, which accounted for about 86% of its total revenue in the third quarter of 2018,
- Markit•3 hours ago
See what the IHS Markit Score report has to say about Walmart Inc.
# Walmart Inc ### NYSE:WMT View full report here! ## Summary * Perception of the company's creditworthiness is neutral * Bearish sentiment is low * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is extremely low for WMT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting WMT. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $8.79 billion over the last one-month into ETFs that hold WMT are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Consumer Services sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. ## Credit worthiness Credit default swap | Neutral The current level displays a neutral indicator. WMT credit default swap spreads are decreasing, indicating some improvement in the market's perception of the company's credit worthiness. Additionally, they are within the middle of the range set over the last three years. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- CNBC•4 hours ago
Target is making a bigger bet on baby
Target is expanding its in-house brand Cloud Island to include essential baby items like diapers, wipes and toiletries. Target says most goods will be competitively priced under $10. Without Babies R Us, Target TGT sees an opportunity to double down on its own baby business.
- Reuters•6 hours ago
Exclusive: India's e-commerce curbs could hit online sales by $46 billion by 2022 - PwC draft analysis
India's new foreign investment restrictions for its e-commerce sector, which includes giants such as Amazon.com Inc and Walmart-owned Flipkart, could reduce online sales by $46 billion by 2022, according to a draft analysis from global consultants PwC seen by Reuters. Under the changes, e-commerce firms in India will from Feb. 1 not be able to sell products via companies in which they have an equity interest or push sellers to sell exclusively on their platforms. Announced in December, just months before a general election due by May this year, the rules were seen as an attempt by Prime Minister Narendra Modi's government to appease millions of small traders and shopkeepers, who form a key voter base and say their businesses have been threatened by global online retailers.
- Motley Fool•16 hours ago
How Costco Crushed It in 2018
The warehouse retailer set some impressive records last year, but even more growth is on the way.
- Zacks•18 hours ago
Amazon Roundup: CES, Whole Foods, AWS, Robotics, Dash, India
Here are the top stories from last week.
- Market Realist•yesterday
Alphabet’s Waymo Now in Serious Business
What to Expect from Alphabet’s Q4 Results(Continued from Prior Part)Waymo officially entered ride-hailing marketAlphabet (GOOGL) is scheduled to report its results for the fourth quarter of 2018 on February 4, marking its first quarterly report
- Zacks•yesterday
Microsoft, WBA Deal to Break AMZN, GOOGL Healthcare Dreams
Microsoft (MSFT) inks a seven-year deal with Walgreens to offer innovative healthcare delivery solutions that can pose threat to Amazon and Google's growing presence.
- Zacks•yesterday
The Zacks Analyst Blog Highlights: Walmart, Comcast, ConocoPhillips, PayPal and CSX
The Zacks Analyst Blog Highlights: Walmart, Comcast, ConocoPhillips, PayPal and CSX
- Zacks•yesterday
6 Reasons Why You Should Invest in Green Dot (GDOT) Stock Now
Fast growing BaaS platform programs, long-lasting relationship with Walmart and a solid balance sheet are positives for Green Dot (GDOT).
- The Wall Street Journal•yesterday
The Morning Download: In Machine Learning Age, Walmart Executive Finds Scale Helps
Executive Vice President Jeremy King, speaking with CIO Journal's Sara Castellanos Sunday at the National Retail Federation event, made an argument for bigness—once considered a negative when competing against digital-first rivals—as a technological driver. “You would be surprised at the list of companies that have completely choked on Walmart’s scale, because no one really builds products for Fortune One,” said Mr. King, who is CTO of all U.S. stores, ecommerce and Walmart Labs. Today, bigness means the retailer's machine learning efforts benefit from data generated by people who shop at Walmart every week and activities around the tens of millions of items on its website.
- GlobeNewswire•yesterday
Market Trends Toward New Normal in Walmart, Finisar, Gannett Co., AZZ, Raytheon, and THL Credit — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Jan. 16, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- MarketWatch•yesterday
Sears Chairman Eddie Lampert prevails with strengthened bid in bankruptcy auction: Reuters
Sears Holdings Corp. Chairman Eddie Lampert prevailed in a bankruptcy auction for the struggling department store chain with an improved takeover bid of roughly $5.2 billion, Reuters reported early Wednesday, citing people familiar with the dealings. The move, if confirmed, would allow the 126-year-old retailer to keep its roughly 425 stores across the U.S. open. Lampert's bid, boosted from an earlier $5 billion, won out after a weeks-long process and a days-long auction held behind closed doors. The billionaire's latest proposal, made through his hedge fund ESL Investments, includes more cash and assumes more liabilities, the sources said, according to Reuters.
- Motley Fool•2 days ago
Target's Digital Strategy Is Paying Off
Online sales continued growing rapidly during the tough holiday season.
- The Wall Street Journal•2 days ago
Walmart Could Leave CVS Caremark Pharmacy Networks Amid Dispute
CVS Health Corp. is battling Walmart Inc. over the cost of filling prescriptions, a clash that could result in a split between the retail behemoth and the health-care giant. Walmart is expected to leave CVS Caremark pharmacy networks over the dispute, a split that could occur as soon as early February, though CVS said it has asked for an extension through April 30. CVS Caremark, the pharmacy-benefits unit of CVS Health, said Monday that Walmart is seeking an increase in what the retailer gets paid for prescriptions, which would “ultimately result in higher costs for our clients and consumers.” CVS Caremark, which is separate from CVS’s retail drugstores, reimburses pharmacies when shoppers with CVS Caremark prescription coverage buy medicine.
- Benzinga•2 days ago
Raymond James: CVS A Strong Buy Despite Pricing Headwinds
Raymond James is making more conservative assumptions and lowered its 2019 earnings per share estimate by 30 cents to $7.40. The Raymond James note was issued before CVS announced later Tuesday that Walmart would no longer participate in the network of providers where customers of some of CVS’s Caremark pharmacy benefit programs can have their prescriptions filled.
- Zacks•2 days ago
Amazon Announces Great Indian Sale, to Offer Deep Discounts
Amazon (AMZN) announces Great Indian Sale, promises hefty discounts across wide range of products on its platform.
- American City Business Journals•2 days ago
Here’s why the Supreme Court might be uncorking wine sales in a city near you
Total Wine & More's effort to open a store in Tennessee set off a legal battle that could upend the wine industry.
- InvestorPlace•2 days ago
How Walmart-CVS Pharmacy Dispute Could Affect Customers
A Walmart-CVS pharmacy dispute is likely going to cause problems for customers. Source: Mike Mozart via Flickr The dispute was announced on Tuesday with CVS (NYSE:CVS) saying that Walmart (NYSE:WMT) is leaving its "pharmacy benefit management (PBM) commercial and Managed Medicaid retail pharmacy networks." The Walmart-CVS pharmacy dispute has to do with pricing. CVS claims that Walmart was seeking reimbursement increases that it claims would result in higher costs for both clients and consumers. CVS refused this request, which is the reason behind the split. InvestorPlace - Stock Market News, Stock Advice & Trading Tips "While we have enjoyed a long relationship with Walmart as a low cost provider in our broad national networks, based on our commitment to helping our clients and consumers manage rising pharmacy costs, we simply could not agree to their recent demands for an increase in reimbursement," Derica Rice, President of CVS Caremark, said in a statement. So how exactly will the Walmart-CVS pharmacy dispute affect customers. It may make it harder for some customers to get their prescriptions filled. However, CVS is working with Walmart to have it act as an in network participating pharmacy through April 30, 2019. * 8 Dividend Stocks With Growth on the Horizon While the Walmart-CVS pharmacy dispute is sure to cause problems for some customers, CVS argues it won't be as bad as it seems. It claims that less than 5% of its members user Walmart pharmacies exclusively. It also says that customers still have plenty of options for filling their prescriptions that are within the same travel distance as WMT locations. CVS stock was down 1% and WMT stock was up 1% as of Tuesday afternoon. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Companies That Could Post Decelerating Profits * 10 A-Rated Stocks the Smart Money Is Piling Into * Mizuho: 7 Long-Term Value Stocks to Buy Now As of this writing, William White did not hold a position in any of the aforementioned securities. Compare Brokers The post How Walmart-CVS Pharmacy Dispute Could Affect Customers appeared first on InvestorPlace.
- CNBC•2 days ago
Blue Apron shares skyrocket after company says it will be profitable in 2019
Shares of Blue Apron skyrocketed after the company said it would likely be profitable in 2019. The company's stock has been in danger of being delisted from the New York Stock Exchange. To help sales, the meal kit service has partnered with Walmart's Jet.com and WW, formerly known as Weight Watchers.
Reuters•2 days agoWalmart opts to leave CVS partnerships over pricing dispute
CVS said the dispute would not impact Walmart's presence in its Medicare Part D pharmacy network, which according to Cowen & Co analyst Charles Rhyee was a bright spot as it represented a larger chunk of CVS' scripts. "At a time when everyone is working hard to find ways to reduce healthcare costs, Walmart's requested rates would ultimately result in higher costs for our clients and consumers," Derica Rice, president of CVS Caremark, said in a statement https://cvshealth.com/newsroom/press-releases/cvs-health-announces-walmart-decision-leave-cvs-caremark-commercial-and. Walmart spokeswoman Marilee McInnis said the retailer was continuing discussions with CVS Caremark, the company's pharmacy benefits unit.
- InvestorPlace•2 days ago
Teladoc Stock Is a Victim of the Market, Not a Bad Buy
A bear market never feels fun amid the pain. However, deflated investor sentiment provides an opportunity for speculators to pick up strong names at fire-sale prices. Such is the case with innovative healthcare firm Teladoc Health (NYSE:TDOC). Despite its potential to dramatically change patient care, Teladoc stock has suffered steep declines. In many ways, the groundbreaking organization is purely a victim of the broader market meltdown. Since its inception, Teladoc has jumped to fame through its distinct platform, which connects licensed medical practitioners with patients. Through the internet, phone, or mobile app, people can immediately receive a diagnosis and counsel from home. Given this powerful opportunity, it's no wonder that TDOC stock captured investor attention. The company enjoyed breakout success in 2017, where shares more than doubled. For the most part, 2018 was also on track to deliver a positive surprise. Between January through the end of September, TDOC had gained over 146%. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 8 Dividend Stocks With Growth on the Horizon But between October to the end of 2018, TDOC suffered an ignominious drop, shedding nearly 43%. Overall, the healthcare firm brought home a very respectable 41% return. Still, I'm sure more than a few shareholders have pondered the missed opportunity. From an outsider's perspective, TDOC presents a clear-cut example of a good company stuck in a bad market. Presumably, without the broader meltdown, shares would have trekked higher. In that case, the present weakness in the innovative company is a perfect contrarian opportunity. But is that really what we're looking at? Both bulls and bears have a strong case. Let's first examine the optimist's perspective: ### Teladoc Could Change Healthcare One of the biggest contributors for a rising price in TDOC stock is that no one likes doctor visits. Of course, they're necessary for maintaining optimal health and for preventing problems from escalating into more serious situations. But at the same time, the reason that you're seeking medical advice usually creates tension. With TDOC's services, you can receive a diagnosis from the comfort of your own home. Moreover, a psychological study revealed that 3% of the U.S. population have a fear of doctors. Teladoc potentially helps alleviate stress among people who are uncomfortable visiting a doctor. Just as important, the network helps promote quick and easy communication between patients and practitioners. This fosters greater health among the population through preventative strategies. Naturally, this dynamic is net positive for Teladoc stock, creating a win-win for all involved parties. While the company will likely spark holistic benefits for American healthcare, Teladoc remains primarily a business. Fortunately, business is good. According to a Transparency Market Research report, the worldwide "telehealth" industry will hit sales of $19.5 billion by 2025. To be fair, this doesn't sound like much against the healthcare behemoth. But the telehealth sector has the most potential to branch out. For instance, its internet-diagnosis method easily crosses borders where physical and political impediments exist. Another factor bolstering the case for Teladoc stock is timing. Increasingly, medical care is becoming personalized. Outside of obvious profitability interests, this trend has influenced non-healthcare companies like Walmart (NYSE:WMT) and Amazon (NASDAQ:AMZN) to participate. Moreover, these retail giants are indirectly imposing a certain mentality to healthcare. Both Walmart and Amazon emphasize convenience at the lowest possible price. TDOC offers the same ethos, but for the doctor-patient relationship. ### Don't Ignore the Risks for Teladoc stock On surface level, the bullish case for TDOC stock appears like a no-brainer. We have a groundbreaking company levered towards a rising, in-demand industry. The only reason that shares have fallen is due to ugliness in the major indices. But don't jump onboard Teladoc stock before you examine the other side. Off the top of my head, a potentially-significant headwind is the barrier to entry. Put simply, Teladoc doesn't have a moat to fend off copycat competitors. The most valuable asset that TDOC enjoys is its network of medical experts and practitioners. Yes, I'm sure the company technically has proprietary methodologies it employs for its communication platforms. But web and mobile channels are not what drives Teladoc stock, but rather, the doctors. As such, the organization remains vulnerable. For healthcare specifically, Teladoc is not a universal panacea. Doctors require hands-on sessions with their patients to extract an accurate diagnosis. Of course, we all know that no profession is perfect. Logically speaking, though, the possibility of a misdiagnosis increases dramatically when the doctor can't really "see" the patient. This headwind segues into another problem, regulation. Although strict guidelines for any medical function exist, telehealth uniformity at the state and national levels does not. Unless we start seeing legislative consensus, multinational corporations probably cannot benefit from this sector's innovations. Plus, you're diving into an area where lawsuits based on misdiagnoses could upset the whole environment. Thus, Teladoc stock is by no means an easy investment. ### Bottom Line for TDOC stock Looking at both sides of the issue, I like TDOC. I believe that the innovations that could change healthcare for the better overcome the risks. That said, I'd urge caution. This is what I would call a "60/40" bull case. Ultimately, the optimists should drive Teladoc stock higher from its current doldrums. However, if you make significant profits, I'd trim exposure. Regulatory hurdles are nasty and can take a long time to resolve. As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Companies That Could Post Decelerating Profits * 10 A-Rated Stocks the Smart Money Is Piling Into * Mizuho: 7 Long-Term Value Stocks to Buy Now Compare Brokers The post Teladoc Stock Is a Victim of the Market, Not a Bad Buy appeared first on InvestorPlace.
Reuters•2 days agoWalmart opts to leave CVS partnerships over pricing dispute
CVS said the dispute would not impact Walmart's presence in its Medicare Part D pharmacy network, which according to Cowen & Co analyst Charles Rhyee was a bright spot as it represented a larger chunk of CVS' scripts. "At a time when everyone is working hard to find ways to reduce healthcare costs, Walmart's requested rates would ultimately result in higher costs for our clients and consumers," Derica Rice, president of CVS Caremark, said in a statement. Walmart spokeswoman Marilee McInnis said the retailer was continuing discussions with CVS Caremark, the company's pharmacy benefits unit.
